⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OSTX News
OS Therapies Incorporated
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
businesswire.com
OSTX
Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
businesswire.com
OSTX
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor Ready to Announce with Confidence?
newsfilecorp.com
OSTX
GENK
PFE
Form 8-K
sec.gov
OSTX
OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors Ready to Announce with Confidence?
newsfilecorp.com
OSTX
Form 8-K
sec.gov
OSTX
OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX